Acumen Pharmaceuticals (ABOS) stock

Market cap $162M

$2.07

-6.76%

Market closed. Prices as of Thursday's close.

Quality Score

-3

Poor

In its industry

#181of 276

Biotech

Checks firing

2of 14

Trending up

From 52-week high

-42.5%

Below the 200-day

NextLate 2026“…1 Phase 2 Phase 3Preclinical Intravenous (IV) Subcutaneous (SC) Phase 2 topline results expected late 2026…”Trial data · 8-K, Sep 16

Cash$110M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “into early 2027”

Follow ABOS's trial news. Pro members can get an alert when Acumen Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when ABOS files news on its trialFree for 24 hours. No account needed.

Cash$110M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “into early 2027”

Pipeline and cash

What's next for ABOS, and how long its cash lasts

From Acumen Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Late 2026“Phase 1 Phase 2 Phase 3Preclinical Intravenous (IV) Subcutaneous (SC) Phase 2 topline results expected late 2026 Phase 1 topline results announced March 2025 support further development as…”Trial data · 8-K, Sep 16

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: ALTITUDE-ADPhase 2 · Active · 542 people · main data estimated Oct 2026 · NCT06335173

For Pro members: 1 more milestone and 28 filings.

Cash runway Jun 30 balance sheet

About 4 quarters

$110M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into early 2027” (8-K, Aug 12).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Mar 27, 2024)
At-the-market share sales program (424B5, filed Nov 13, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Derrell Porter sold 32,300 shares on Jun 17. 20 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Daniel OConnell buys or sells

For Pro members: every trade, and Daniel OConnell’s 6 filings and quotes.

Get an optional alert when ABOS files news on its trialFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $122MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $130MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $486MDrug not namedUnder FDA review

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why ABOS scores -3

PoorTrending up, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

Well below its own recent run. ABOS scores -3 today, against a median of 1.5 over its last 20 recorded sessions.

+2Chart checks 2 of 14 firing right now, one point each
−2Volatility moves 9.5% a day on a $105M loss over four quarters, with no positive free cash flowA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

Size subtracts
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Run-up, Profit, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on ABOS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:06 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 11, before the open

After its last 4 reports it closed -1.5% on average, higher 1 of 4 times.

What would turn ABOS's score around: 8 things, for Pro members

Alert me when ABOS's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart — A stock page

The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist — The scanner

The 14 checks

ABOS has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on ABOS, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1430.2
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line 16 sessions ago.
50-day average$2.61
The price is 20.7% below it.
200-day average$2.51
The price is 17.5% below it. The 50-day is above the 200-day, since Aug 14.
ADX 1424.5
Under 25, with +DI below -DI.
Support$1.90
Swing low from Dec 30, 2025, 8.2% below the price.
Resistance$2.39
Swing high from Dec 22, 2025, 15.5% above the price.
Bollinger Bands (20, 2)Inside
The bands run from $1.95 to $3.29.
Volume1.6x
Against its 20-day average, for the time of day.

Its industry

How ABOS ranks in Biotech

ABOS is #181 of 276 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2ABCLAbCellera Biologics6/1416
3OABIOmniAb9/1415
ABEOAbeona TherapeuticsOpen for its score
ABVXAbivax SAOpen for its score
ADPTAdaptive BiotechnologiesOpen for its score
181ABOSAcumen Pharmaceuticals2/14-3

When does ABOS report earnings, and what happens after?

Expected to report Wed Nov 11, before the open (in 40 days). Not yet confirmed by the company.

-1.0%-3.0%-3.5%+1.6%

Nov 12Mar 26May 12Aug 12

Reported	When	Gap	Reaction	5 sessions
Aug 12, 2026Before open	Before open	-2.4%	+1.6%	+10.9%
May 12, 2026Before open	Before open	+0.4%	-3.5%	-15.2%
Mar 26, 2026Before open	Before open	-2.7%	-3.0%	-3.0%
Nov 12, 2025Before open	Before open	+0.5%	-1.0%	-15.7%

The gap is the next open against the close before the report; the reaction is where that session closed. ABOS closed higher after 1 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Filings

Who is trading ABOS

ABOS insider trades

2 insiders sold $90K across 4 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellDerrell Porter$30KDirectorat $2.33 on Jun 17, filed Jun 17

SellDerrell PorterDirector$30Kat $2.33 on Jun 17, filed Jun 17

All 4 insider filings on ABOS from the last six months, for Pro members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

The company

About Acumen Pharmaceuticals

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

61 employeesNewton, MAacumenpharm.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of ABOS's score, with the points and the reason
All 14 checks on ABOS and on all 2,958 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on ABOS

BreakawayJun 17Derrell Porter sold ABOS$30K at $2.33, filed Jun 17

What a filing on ABOS would have sent. Alerts are optional.

See all 14 checks on ABOSFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.